



FORM PTO-1449/A and B (Modified)

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

Sheet 1 of 9

APPLICATION NO.: 10/627,331

ATTY. DOCKET NO.: C1039.70078US00

FILING DATE: July 25, 2003

CONFIRMATION NO.: 4362

APPLICANT: Arthur M. Krieg, et al.

GROUP ART UNIT: 1648

EXAMINER: Emily Le

## **FOREIGN PATENT DOCUMENTS**

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
	*	GB	2216416A		Sandoz, Ltd.	11-10-1989	
	*	WO	91/12811		PCT	09-05-1991	
	*	EPO	0468520 A3		EPO	01-29-1992	
	*	WO	92/03456		PCT	03-05-1992	
	*	WO	92/18522		PCT	10-29-1992	
	*	WO	92/21353		PCT	12-10-1992	
	*	EPO	0302758 81		EPO	03-16-1994	
	*	WO	94/19945		PCT	09-15-1994	
	*	WO	95/05853		Regents of the University of CA	03-02-1995	
	*	WO	95/26204		PCT	10-05-1995	
	*	WO	96/02555		PCT	02-01-1996	
	*	WO	96/35782		Applied Research Systems	11-14-1996	
	*	WO	97/28259		PCT	08-07-1997	
	*	WO	98/14210		PCT	04-09-1998	
	*	WO	98/16247		Regents of the University of CA	04-23-1998	
	*	WO	98/18810		PCT	05-07-1998	
	*	WO	98/32462	A1	Wagner et al.	07-30-1998	
	*	WO	98/37919		PCT	09-03-1998	
	*	WO	98/40100		PCT	09-17-1998	
	*	WO	98/52581		PCT	11-26-1998	
	*	WO	98/55495	A2	Dynavax Tech. Corp.	03/11/1998	
	*	WO	99/11275	A2	Regents of the University of CA	03-11-1999	
	*	WO	99/62923	A2	Dynavax Tech. Corp	12/09/1999	
	*	WO	00/20039	A1	Regents of the University of CA	04/13/2000	

FORM PTO-1449/A and B (Modified)				APPLICATION NO.: 10/627,331		ATTY. DOCKET NO.: C1039.70078US00			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				FILING DATE: July 25, 2003		CONFIRMATION NO.: 4362			
				APPLICANT: Arthur M. Krieg, et al.					
				GROUP ART UNIT: 1648		EXAMINER: Emily Le			
Sheet	2	of	9						

#### FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
	*	WO	00/21556	A1	Dynavax Tech Corp.	04/20/2000	
	*	WO	00/62781	A1	Regents of the University of CA	10/26/2000	
	*	WO	01/02007	A1	The Reagents of the Univ. of California	01-11-2001	
	*	WO	01/12804	A2	Hybridon, Inc.	02-22-2001	
	*	WO	01/12223	A2	Dynavax Tech. Corp.	02-22-2001	
	*	WO	01/55341	A2	The Reagents of the Univ. of California	08-02-2001	
	*	WO	01/68117	A2	Dynavax Tech. Corp.	09-20-2001	
	*	WO	01/68116	A2	Dynavax Tech. Corp.	09-20-2001	
	*	WO	01/68078	A2	Dynavax Tech. Corp.	09-20-2001	
	*	WO	01/68077	A2	Dynavax Tech. Corp.	09-20-2001	
	*	WO	01/68103	A2	Dynavax Tech. Corp.	09-20-2001	

#### OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.					Translation (Y/N)
	*	ADYA N et al., Expansion of CREB's DNA recognition specificity by Tax results from interaction with Ala-Ala-Arg at positions 282-284 near the conserved DNA-binding domain of CREB. <i>Proc Natl Acad Sci USA</i> (1994) 91(12):5642-6.					
	*	AGRAWAL, et al., Pharmacokinetics of Antisense Oligonucleotides, <i>Clin. Pharmacokinet</i> (1995) 28(1):7.					
	*	ANDERSON, G., et al. "TH2 and 'TH2-like' cells in allergy and asthma; pharmacological perspectives", <i>TIPS</i> , 15:324-332, (1994)					
	*	ANGIER, N., Microbe DNA Seen as Alien By Immune System, <i>New York Times</i> , 4/11/95.					
	*	AZAD RF et al., Antiviral Activity of a Phosphorothioate Oligonucleotide Complementary to RNA of the Human Cytomegalovirus Major Immediate-Early Region, <i>Antimicrobial Agents and Chemotherapy</i> , 37:1945-1954, September, 1993.					
	*	AZUMA, Biochemical and Immunological Studies on Cellular Components of Tubercle Bacilli, <i>Kekkaku</i> , (1992) Vol. 69, 9:45-55.					
	*	BALLAS ZK et al., Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. <i>J Immunol</i> (1996) 157(5):1840-5.					
	*	BAYEVER, E., Systemic Administration of a Phosphorothioate Oligonucleotide with a Sequence Complementary to p53 for Acute Myelogenous leukemia and Myelodysplastic Syndrome: Initial Results of a Phase I Trial, <i>Antisense Res. &amp; Dev.</i> (1993), 3:383-390.					
	*	BENNETT RM et al., DNA binding to human leukocytes. Evidence for a receptor-mediated association, internalization, and degradation of DNA. (1985) <i>J Clin Invest</i> 76(6):2182-90.					
	*	BERG DJ et al., Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. <i>J Clin Invest</i> (1995) 96(5):2339-47.					
	*	BLANCHARD DK et al., Interferon-gamma induction by lipopolysaccharide: dependence on interleukin 2 and macrophages. <i>J Immunol</i> (1986) 136(3):963-70.					
	*	BLAXTER et al., Genes expressed in <i>Brugia malayi</i> infective third stage larvae. <i>Molecular and</i>					

Biochemical Parasitology, 77:77-93.			
FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 10/627,331	ATTY. DOCKET NO.: C1039.70078US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: July 25, 2003	CONFIRMATION NO.: 4362
		APPLICANT: Arthur M. Krieg, et al.	
		GROUP ART UNIT: 1648	EXAMINER: Emily Le
Sheet	3	of	9

#### OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	*	BOGGS RT et al., Characterization and modulation of immune stimulation by modified oligonucleotides. <i>Antisense Nucleic Acid Drug Dev</i> (1997) 7(5):461-71.	
	*	BRANDA et al., Immune Stimulation by an Antisense Oligomer Complementary to the rev gene of HIV-1, <i>Biochemical Pharmacology</i> , (1993) Vol. 45, 10:2037-2043.	
	*	BRANDA RF et al., Amplification of antibody production by phosphorothioate oligodeoxynucleotides, <i>J. Lab Clin Med</i> (1996) 128(3):329-38.	
	*	BRISKIN M et al., Lipopolysaccharide-unresponsive mutant pre-B-cell lines blocked in NF-kappa B activation, (1990) <i>Mol Cell Biol</i> 10(1):422-5.	
	*	CHACE, J. et al., Regulation of Differentiation in CD5+ and Conventional B Cells, <i>Clinical Immunology and Immunopathology</i> , (1993) 68:3:327-332.	
	*	CHANG YN et al., The palindromic series I repeats in the simian cytomegalovirus major immediate-early promoter behave as both strong basal enhancers and cyclic AMP response elements, <i>J Virol</i> (1990) 64(1):264-77.	
	*	CHU RS et al., CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity, (1997) <i>J Exp Med</i> 186(10):1623-31..	
	*	COSSUM et al., Pharmacokinetics of a 14C-Labeled Phosphorothioate Oligonucleotide, <i>ISIS 2105, after Intradermal Administration to Rats</i> , <i>J Pharmacol Exp Therapeutics</i> (1993) 269(1):89.	
	*	COWDERY JS et al., Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides, <i>J Immunol</i> (1996) 156(12):4570-5.	
	*	CROSBY et al., The Early Responses Gene FGF1-C Encodes a Zinc Finger Transcriptional Activator and is a Member of the GCGGGGCGC (GSG) Element-Binding Protein Family, <i>Mol. Cell. Biol.</i> (1991) 2:3835-3841.	
	*	CRYSTAL, Transfer of Genes to Humans: Early Lessons and Obstacles to Success. <i>Science</i> , (1995) Vol. 270, pp. 404-410.	
	*	D'ANDREA A et al., Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells, <i>J Exp Med</i> (1993) 178(3):1041-8.	
	*	ELKINS, K. L., Rhinehart-Jones, T. R., et al., "Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria." <i>J Immunol</i> 162:2291-2298, 1999.	
	*	ENGLISH et al., Chemically Modified Oligonucleotides as Probes and Inhibitors, <i>Angew. Chem. Int. Ed. Engl</i> (1991) 30:613-629.	
	*	ERB KJ et al., Infection of mice with Mycobacterium bovis-Bacillus Calmette-Guerin (BCG) suppresses allergen-induced airway eosinophilia, <i>J Exp Med</i> (1998) 187(4):561-9..	
	*	ETLINJER, Carrier sequence selection - one key to successful vaccines, <i>Immunology Today</i> , (1992) Vol. 13, 2:52-55.	
	*	FOX RI, Mechanism of action of hydroxychloroquine as an antirheumatic drug. <i>Chemical Abstracts</i> , (1994) 120:15, Abstract No. 182630.	
	*	FREIDAG, B. L. et al., "CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis.: <i>Infect Immun</i> 68:2948-2953, 2000.	
	*	GAO, W-Y et al., Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and Rnase H: Implications for antisense technology. <i>Mol. Pharmacol.</i> (1992), 41, 223-229.	
	*	GURA, T., Antisense Has Growing Pains. <i>Science</i> (1995), 270:575-576.	
	*	HADDEN J et al., Immunopharmacology, <i>JAMA</i> , (1992) 268:20:2964-2969.	

FORM PTO-1449/A and B (Modified)			APPLICATION NO.: 10/627,331	ATTY. DOCKET NO.: C1039.70078US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			FILING DATE: July 25, 2003	CONFIRMATION NO.: 4362
			APPLICANT: Arthur M. Krieg, et al.	
			GROUP ART UNIT: 1648	EXAMINER: Emily Le
Sheet	4	of	9	

**OTHER ART — NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	*	HADDEN J et al., Immunostimulants. <i>TIPS</i> , (1993), 141:169-174.	
	*	HALPERN MD et al., Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. <i>Cell Immunol</i> (1996) 167(1):72-8.	
	*	HATZFELD J., Release of Early Human Hematopoietic Progenitors from Quiescence by Antisense Transforming Growth Factor $\beta$ 1 or Rb Oligonucleotides. <i>J. Exp. Med.</i> , (1991) 174:925-929.	
	*	HAYASHI, T. et al., "Enhancement of innate immunity against Mycobacterium avium infection by immunostimulatory DNA is mediated by indoleamine 2,3-dioxygenase." <i>Infect Immun</i> 69:6156-6164, 2001.	
	*	HIGHFIELD PE, Sepsis: the More, the Murkier. <i>Biotechnology</i> , (1994) 12:828.	
	*	HOEFFLER JP et al., Identification of multiple nuclear factors that interact with cyclic adenosine 3',5'-monophosphate response element-binding protein and activating transcription factor-2 by protein-protein interactions., (1994) <i>Mol Endocrinol</i> 5(2):256-66.	
	*	HORSPOOL JH et al., Nucleic acid vaccine-induced immune responses require CD28 costimulation and are regulated by CTLA4. (1998) <i>J. Immunol.</i> 160, 2706-2714.	
	*	IGUCHI-ARIGA SM and Shaffner W, CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation. <i>Genes Dev</i> (1989) 3(5):612-9.	
	*	ISHIKAWA R et al., IFN induction and associated changes in splenic leukocyte distribution. <i>J Immunol</i> (1993) 150(9):3713-27.	
	*	IVERSON, P., et al., "Pharmacokinetics of an Antisense Phosphorothioate Oligodeoxynucleotide against rev from Human Immunodeficiency Virus Type 1 in the Adult male Rat Following Single Injections and Continuous Infusion", <i>Antisense Research and Development</i> , (1994) 4:43-52.	
	*	JAKWAY JP et al., Growth regulation of the B lymphoma cell line WEHI-231 by anti-immunoglobulin, lipopolysaccharide, and other bacterial products. <i>J Immunol</i> (1986) 137(7):2225-31.	
	*	JAROSZEWSKI JW and Cohen JS, Cellular uptake of antisense oligonucleotides. <i>Adv Drug Delivery Rev</i> (1991) 6(3):235-50.	
	*	JONES TR et al., Synthetic oligonucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. <i>Vaccine</i> (1999) 17, 3065-3071.	
	*	JUFFERMANS, N. P. et al., "CpG oligodeoxynucleotides enhance host defense during murine tuberculosis." <i>Infect Immun</i> 70:147-152, 2002.	
	*	KATAOKA, T. et al., Antitumor Activity of Synthetic Oligonucleotides with Sequences from cDNA Encoding Proteins of Mycobacterium bovis BCG. <i>JPN. J. Cancer Res.</i> (1992) 83:244.	
	*	KAWANO, K., et al., "Analysis and Regulation of interferon-gamma production by peripheral blood lymphocytes from patients with bronchial asthma", ABSTRACT, <i>Aerugi</i> , 43:3:482-91, (1994)	
	*	KIMURA Y et al., Binding of Oligoguanylate to Scavenger Receptors Is Required for Oligonucleotides to Augment NK Cell Activity and Induce IFN, <i>J. Biochem.</i> , (1994) Vol. 116, 5:991-994.	
	*	KLINKE JN et al., CpG motif oligonucleotides are effective in prevention of eosinophilic inflammation in a murine model of asthma. <i>J Invest Med</i> (1996) 44(7):380A.	
	*	KLINKE JN et al., CpG oligonucleotides can reverse as well as prevent Th2-mediated inflammation in a murine model of asthma. <i>J Invest Med</i> (1997) 45(7):298A.	
	*	KLINKE JN et al., "Immune redirection by CpG oligonucleotides. Conversion of a Th2 response to a Th1 response in murine model of asthma." <i>J. Invest Med.</i> 45(3):282A, 1997.	

FORM PTO-1449/A and B (Modified)			APPLICATION NO.: 10/627,331	ATTY. DOCKET NO.: C1039.70078US00	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			FILING DATE: July 25, 2003	CONFIRMATION NO: 4362	
			APPLICANT: Arthur M. Krieg, et al.		
			GROUP ART UNIT: 1648	EXAMINER: Emily Le	
Sheet	5	of	9		

**OTHER ART — NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	*	KLINMAN DM et al., CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. <i>Proc Natl Acad Sci USA</i> (1996) 93(7):2879-83.	
	*	KLINMAN, D. et al., <i>Immune Recognition of Foreign DNA: A Cure for Bioterrorism?</i> , <i>Immunity</i> (1999) 11:123.	
	*	KLINMAN, D. M. et al., "Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection. <i>Infect Immun</i> 67:5658-5663, 1999"	
	*	KLINMAN, D. M., Kamstrup, S., Verthelyi, D., Gursel, I., Ishii, K. J., Takeshita, F., and Gursel, M. Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety. <i>Springer Semin Immunopathol</i> 22:173-183, 2000	
	*	KRIEG, A. M., et al., "CpG DNA induces sustained IL-12 expression <i>in vivo</i> and resistance to <i>Listeria monocytogenes</i> challenge." <i>J Immunol</i> 161:2428-2434, 1998.	
	*	KRIEG, CpG Motifs in Bacterial DNA and Their Immune Effects, <i>Annu. Rev. Immunol.</i> (2002) 20:709	
	*	KRIEG AM et al, A Role for Endogenous Retroviral Sequences in the Regulation of Lymphocyte Activation, <i>Journal of Immunology</i> , Vol. 143, 2448-2451	
	*	KRIEG AM et al, The role of CpG dinucleotides in DNA vaccines, <i>Trends in Microbiology</i> , Vol. 6, pp. 23-27, Jan 1998.	
	*	KRIEG AM et al, Phosphorothioate Oligodeoxynucleotides: Antisense or Anti-Protein?, <i>Antisense Research and Development</i> , (1995), 5:241	
	*	KRIEG AM et al., CpG DNA: A Pathogenic Factor in Systemic Lupus Erythematosus?, <i>Journal of Clinical Immunology</i> , (1995) 15:6:284-292	
	*	KRIEG AM et al., CpG motifs in bacterial DNA trigger direct B-cell activation. <i>Nature</i> 374:546-9, 1995.	
	*	KRIEG AM et al., Leukocyte Stimulation by Oligodeoxynucleotides, <i>Applied Antisense Oligonucleotide Technology</i> , (1998), 431-448	
	*	KRIEG AM et al., Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholesteryl moiety increases cellular association and improves efficacy, <i>Proc. Natl. Acad. Sci.</i> , (1993), 90:1048-1052.	
	*	KRIEG AM et al., Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. <i>Antisense Nucleic Acid Drug Dev</i> (1996) 6(2):133-9.	
	*	KRIEG AM et al., Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible. <i>Antisense Res Dev</i> (1991) 1(2):161-71.	
	*	KRIEG AM, An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA. <i>J Lab Clin Med</i> (1996) 128(2):128-33.	
	*	KURAMOTO et al., Oligonucleotide Sequences Required for Natural Killer Cell Activation, <i>Jpn. J. Cancer Res.</i> , (1992) 83:1128-1131.	
	*	LAGRANGE et al., Immune Responses Directed Against Infectious and Parasitic Agents, <i>Principle Types of Immune Responses</i> .	
	*	LEONARD et al., Conformation of Guanine 8-Oxoadenine Base Pairs in the Crystal Structure of d(CGCGAATT(08A)GCG), <i>Biochemistry</i> (1992) 31(36):8415-8420.	
	*	LIPFORD G. B. et al. "Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines." <i>Eur J Immunol</i> 27:3420-3426, 1997.	
	*	MACFARLANE DE and Manzel L, Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinaquine, chloroquine, and structurally related compounds. <i>J Immunol</i> (1998) 160(3):1122-31.	
	*	MANZEL L and Macfarlane DE, Lack of Immune Stimulation by Immobilized CpG-oligonucleotide. <i>Antisense &amp; Nucleic Acid Drug Development</i> , (1999) 459-464.	

FORM PTO-1449/A and B (Modified)			APPLICATION NO.: 10/627,331	ATTY. DOCKET NO.: C1039.70078US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			FILING DATE: July 25, 2003	CONFIRMATION NO.: 4362
			APPLICANT: Arthur M. Krieg, et al.	
			GROUP ART UNIT: 1648	EXAMINER: Not yet assigned
Sheet	6	of	9	

**OTHER ART — NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	*	MASTRANGELO MJ et al., Gene therapy for human cancer: an essay for clinicians. <i>Seminars in Oncology</i> (1996) 23(1):4-21.	
	*	MATSON S and Krieg AM, Nonspecific suppression of [3H]thymidine incorporation by "control" oligonucleotides. <i>Antisense Res Dev</i> (1992) 2(4):325-30.	
	*	MCINTYRE KW et al., A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-kappa B p65 causes sequence-specific immune stimulation. <i>Antisense Res Dev</i> (1993) 3(4):309-22.	
	*	MESSINA et al., Stimulation of <i>in vitro</i> Murine Lymphocyte Proliferation by Bacterial DNA. <i>J. Immunol.</i> , (1991) Vol. 147, 6:1759-1764.	
	*	MESSINA et al., The influence of DNA Structure on the <i>in vitro</i> Stimulation of Murine Lymphocytes by Natural and Synthetic Polynucleotide Antigens. <i>Cellular Immunology</i> , (1993) 147:148-157.	
	*	MOJCIK, C., et al., Administration of a Phosphorothioate Oligonucleotide Antisense Murine Endogenous Retroviral MCF env Causes Immune Effect in vivo in a Sequence-Specific Manner, <i>Clinical Immunology and Immunopathology</i> , (1993) 67:2:130-136.	
	*	MOTTRAM et al., A novel CDC2-related protein kinase from Leishmania mexicana LmmCRK1 is post-translationally regulated during the life cycle. <i>J. Biol. Chem.</i> (1993) 268:28, 21044-21052.	
	*	<i>New England BIOLABS 1988-1989 Catalog</i>	
	*	NYCE JW and Metzger WJ, DNA antisense therapy for asthma in an animal model. <i>Nature</i> (1997) 385:721-725.	
	*	PISETSKY DS, The immunologic properties of DNA. <i>J Immunol</i> (1996) 156(2):421-3.	
	*	PISETSKY et al., Stimulation of Murine Lymphocyte Proliferation by a Phosphorothioate Oligonucleotide with Antisense Activity for Herpes Simplex Virus. <i>Life Science</i> , (1994) Vol. 54, pp. 101-107.	
	*	PISETSKY, D., "Stimulation of <i>in vitro</i> proliferation of murine lymphocytes by synthetic oligodeoxynucleotides", <i>Molecular Biology Repairs</i> , (1993) 18:217-221.	
	*	PISETSKY, Immunological Consequences of Nucleic Acid Therapy, <i>Antisense Research and Development</i> , (1995) 5:219-225.	
	*	RAZ E et al., Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. <i>Proc Natl Acad Sci USA</i> (1996) 93(10):5141-5.	
	*	RICCI, M., et al., "T cells, cytokines, IgE and allergic airways inflammation", <i>J invest Allergol Clin Immunol</i> , 4:5:214-220, (1994)	
	*	ROMAN M et al., Immunostimulatory DNA sequences function as T helper-I-promoting adjuvants. <i>Nat Med</i> (1997) 3(8):849-54.	
	*	SATO et al., Immunostimulatory DNA Sequences Necessary for Effective Intradermal Gene Immunization, <i>Science</i> , (1996) Vol. 273, pp. 352-354.	
	*	SCHNELL et al., Identification and characterization of a Saccharomyces cerevisiae gene (PAR1) conferring resistance to iron chelators. <i>Eur. J. Biochem.</i> , 200:487-493.	
	*	SCHWARTZ DA et al., CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract. <i>J Clin Invest</i> (1997) 100(1):68-73.	
	*	SCHWARTZ DA et al., Endotoxin responsiveness and grain dust-induced inflammation in the lower respiratory tract. <i>Am J Physiol</i> (1994) 267(5 Pt 1):L609-17.	
	*	SCHWARTZ DA et al., The role of endotoxin in grain dust-induced lung disease. <i>Am J Respir Crit Care Med</i> (1995) 152(2):603-8.	

FORM PTO-1449/A and B (Modified)			APPLICATION NO.: 10/627,331	ATTY. DOCKET NO.: C1039.70078US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			FILING DATE: July 25, 2003	CONFIRMATION NO.: 4362
			APPLICANT: Arthur M. Krieg, et al.	
			GROUP ART UNIT: 1648	EXAMINER: Not yet assigned
Sheet	7	of	9	

**OTHER ART — NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	*	SEDEGAH, M. et al. "Interleukin 12 induction of interferon g-dependent protection against malaria." <i>Proc Natl Acad Sci U S A</i> 91:10700-10702, 1994.	
	*	SETHI, S. et al. "Postexposure prophylaxis against prion disease with a stimulator of innate immunity." <i>Lancet</i> 360:229-230, 2002.	
	*	SHIRAKAWA T et al., The inverse association between tuberculin responses and atopic disorder. <i>Science</i> (1997) 275(5296):77-9.	
	*	SPARWASSER T et al., Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. <i>Eur J Immunol</i> (1997) 27(7):1671-9.	
	*	SPIEGELBERG, H., et al., "Recognition of T Cell Epitopes and Lymphokine Secretion by Rye Grass Allergen Lolium perenne l-Specific Human T Cell Clones", <i>J of Immunology</i> , 4706-4711, (1994)	
	*	STACEY, K. J et al. "Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major." <i>Infect Immun</i> 67:3719-3726, 1999.	
	*	STEIN CA et al., Oligonucleotides as inhibitors of gene expression: a review. <i>Cancer Research</i> , (1988) 48:2659-2668.	
	*	STULL et al., Antigene, Ribozyme, and Aptamer Nucleic Acid Drugs: Progress and Prospects, <i>Pharmaceutical Res.</i> , (1995) Vol. 12, 4:465-483.	
	*	SUBRAMANIAN et al., Theoretical Considerations on the "Spine of Hydration" in the Minor Groove of d(CGCGAATTCGCG) d(GCGCTTAAGCGC): Monte Carlo Computer Simulation. <i>Proc. Nat'l. Acad. Sci. USA</i> , (1988) 85:1836-1840.	
	*	TANAKA T et al., An antisense Oligonucleotide complementary to a sequence in IG2b increases G2b germine transcripts stimulates B cell DNA synthesis and inhibits immunoglobulin secretion. <i>J. Exp. Med.</i> , (1992) 175:597-607.	
	*	THORNE PS., Experimental grain dust atmospheres generated by wet and dry aerosolization techniques. <i>Am J Ind Med</i> (1994) 25(1):109-12.	
	*	TOKUNAGA T et al., A synthetic single-stranded DNA, poly(dG,dC), induces interferon-alpha/beta and -gamma, augments natural killer activity, and suppresses tumor growth. <i>Jpn J Cancer Res</i> (1988) Jun;79(6):682-6.	
	*	TOKUNAGA T et al., Synthetic Oligonucleotides with Particular Base Sequences form the cDNA Encoding Proteins of <i>Mycobacterium bovis</i> BCG Induce Interferons and Activate Natural Killer Cells, <i>Microbiol. Immunol.</i> , (1992) Vol. 36, 1:55-66.	
	*	UHLMANN et al., Antisense Oligonucleotides: A New Therapeutic Principle. <i>Chemical Reviews</i> , (1990) 90:543-584.	
	*	WAGNER RW, Gene inhibition using antisense oligodeoxynucleotides. <i>Nature</i> , (1994) 372:L333-335.	
	*	WALKER, P. S. et al. "Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-g-dependent mechanisms." <i>Proc Natl Acad Sci U S A</i> 96:6970-6975, 1999.	
	*	WALKER, C., et al., "Activated T Cells and Cytokines in Bronchoalveolar Lavages from Patients with Various Lung Diseases Associated with Eosinophilia", <i>Am J Respir Crit Care Med</i> , 150:1038-1048, (1994)	
	*	WALLACE et al., Oligonucleotide probes for the screening of recombinant DNA libraries. <i>Methods in Enzymology</i> , (1987) 152:432-442.	
	*	WEISS R., Upping the Antisense Ante: Scientists bet on profits from reverse genetics. <i>Science</i> , (1991) 139:108-109.	

FORM PTO-1449/A and B (Modified)			APPLICATION NO.: 10/627,331	ATTY. DOCKET NO.: C1039.70078US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			FILING DATE: July 25, 2003	CONFIRMATION NO.: 4362
			APPLICANT: Arthur M. Krieg, et al.	
			GROUP ART UNIT: 1648	EXAMINER: Not yet assigned
Sheet	8	of	9	

#### OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	*	WHALEN R, DNA Vaccines for Emerging Infection Diseases: What If?, <i>Emerging Infectious Disease</i> , (1996) Vol. 2, 3:168-175.	
	*	WOOLDRIDGE, JE et al., Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. <i>Blood</i> , (1997)89:2994-2998.	
	*	WU GY et al., Receptor-mediated gene delivery and expression in vivo. <i>J. Biol. Chem.</i> , (1988) 263:14621-14624.	
	*	WU-PONG S., Oligonucleotides: Opportunities for Drug Therapy and Research. <i>Pharmaceutical Technology</i> , (1994) 18:102-114.	
	*	YAMAMOTO et al., Lipofection of Synthetic Oligodeoxyribonucleotide Having a Palindromic Sequence AACGTT to Murine Splenocytes Enhances Interferon Production and Natural Killer Activity. <i>Microbiol. Immunol.</i> , (1994) Vol. 38, 10:831-836.	
	*	YAMAMOTO S et al., DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. <i>Microbiol Immunol</i> (1992) 36(9):983-97.	
	*	YAMAMOTO S et al., <i>In vitro</i> augmentation of natural killer cell activity and production of interferon-alpha/beta and -gamma with deoxyribonucleic acid fraction from <i>Mycobacterium bovis</i> BCG. <i>Jpn J Cancer Res</i> (1988) 79:866-73.	
	*	YAMAMOTO S et al., Unique Palindromic Sequences in Synthetic Oligonucleotides are Required to Induce INF and Augment INF-Mediated Natural Killer Activity. <i>J. Immunol.</i> , (1992) Vol. 148, 12:4072-4076.	
	*	YAMAMOTO S., Mode of Action of Oligonucleotide Fraction Extracted from <i>Mycobacterium bovis</i> BCG, <i>Kekkaku</i> , (1994) Vol. 69, 9:29-32.	
	*	YAMAMOTO T et al., Ability of Oligonucleotides with Certain Palindromes to Induce Interferon Production and Augment Natural Killer Cell Activity is Associated with Their Base Length. <i>Antisense Res. and Devel.</i> , (1994) 4:119-123.	
	*	YAMAMOTO T et al., Synthetic Oligonucleotides with Certain Palindromes Stimulate Interferon Production of Human Peripheral Blood Lymphocytes <i>in vitro</i> . <i>Jpn. J. Cancer Res.</i> , (1994) 85:775-779.	
	*	YI, Ae-Kyung et al., Rapid Immune Activation by CpG Motifs in Bacterial DNA, <i>J Immunol</i> , (1996) 157:5394-5402.	
	*	YI, A-K et al., IFN- $\gamma$ promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligonucleotides, <i>J Immunol</i> (1996)156(2):558-64.	
	*	ZELPHATI, O et al., Inhibition of HIV-1 Replication in Cultured Cells with Antisense Oligonucleotides Encapsulated in Immunoliposomes, <i>Antisense Research and Development</i> (1993) 3:323.	
	*	ZHAO Q et al., Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. <i>Antisense Res Dev</i> (1993).	
	*	ZHAO Q et al., Stage-specific oligonucleotide uptake in murine bone marrow B-cell precursors. <i>Blood</i> (1994) 84(11):3660-6.	



FORM PTO-1449/A and B (Modified)				APPLICATION NO.: 10/627,331	ATTY. DOCKET NO.: C1039.70078US00
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				FILING DATE: July 25, 2003	CONFIRMATION NO.: 4362
				APPLICANT: Arthur M. Krieg, et al.	
				GROUP ART UNIT: 1648	EXAMINER: Not yet assigned
Sheet	9	of	9		

**OTHER ART — NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	*	ZIMMERMANN, S. et al., "CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis." <i>J Immunol</i> 160:3627-3630, 1998.	

EXAMINER	DATE CONSIDERED
----------	-----------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to applicant.

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in one of the following prior applications, Serial No. 08/386,063, filed 02/07/95, Serial No. 08/738,652, filed 10/30/96, Serial No. 08/960,774, filed 10/30/97, Serial No. 09/630,319, filed 7/31/00, or Serial No. 10/187,489, filed 7/2/2002 relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]